U.S. Markets closed

Horizon Pharma Public Limited Company (HZNP)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.20+0.23 (+2.31%)
At close: 4:00PM EDT
People also watch
DEPOSRPTRDUSCLVSJUNO
  • Email sent today to the top 5 executives at HZNP:
    "With the HZNP stock near 3 year lows, investors have lost some faith in management's ability to lead.
    Now would be an ideal time for management to do some insider buying as a way to show you have confidence in HZNP's future.
    Talk is cheap, but spending your own money on HZNP stock now would demonstrate your confidence."

    I encourage other investors here to send an email as well. It certainly doesn't hurt.
  • MACD beginning to turn up RSI at 27.60 so oversold for now. Should see a pop up soon?
    GLTA
  • Presentations in June
    Jefferies 2017 Global Healthcare Conference

    Date: June 6, 2017
    Presentation Time: 11:30 a.m. ET
    Location: New York, NY
    The JMP Securities Life Science Conference

    Presentation Date: June 21, 2017
    Presentation Time: 1:30 p.m. ET
    Location: New York, NY
    GLTS
  • Well at least Horizon is one of the best places to work in Chicago.... (SARCASM)
  • 1% to 2% drop a day will shake out remaining large investors. I am afraid if HZNP is heading to its old prices of low single digit.
  • Nice story in "The Street"...thinks HZNP is poised for a break-out.
  • has to be the most under valued pharma stock out there. and we own it..
  • they sell a non performing asset for 70 million with what did they say only 15 million in sales and the stock goes down? a bit odd. but its hznp so it doesn't surprise me
  • Company Stratergies
    Now that the company has sold some assets, what should they do with the funds?
    1- I'm still perplexed as to why management hasn't bought more shares.
    Does this tell us they're not confident with the business?
    2- Why hasn't the company at least tried to regain shareholder confindevce with a share buyback.
    Come on guys. You're getting paid very well and we're not at the moment.
    We can't wait forever!
  • Sold HZNP and bought MNK so I am out. Good luck to you all, but I have more confidence in MNK making big gains in the next few months. I am already up over 1%. good luck
  • Waiting for the next shoe?
  • hey who really cares about the stock price as long as hznp is one of the best work places in Chicago. use our money to treat employees to good times.
  • Use the cash to by an orphan drug or orphan drug candidate and maybe some share buy-back. If any left over, pay down debt. Exact strategy that the street is looking for. Of course, ME, a d DEPO holder who owns 0 HZNP shares, is bashing the deal because DEPO has nothing to sell and an opioid abuse investigation.
  • HZNP beginning to SELL non essential assets. 70 million for more purchases or pay down debt. Loss of 15 million revenue so getting about 5 X revenue so far.
    Horizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.
    GLTA
  • horizon named one of the best work places on Chicago. should be named one of the worst stocks to own in Chicago
  • What will happen to HZNP when the market goes red? If HZNP performance is miserable in green market then we should see a huge drop when red market is back.
  • HZNP stock isn't a buy until Shelly throws in the towel. With his huge losses, it sounds like he is getting close to doing that. Stay tuned.
  • Hey Me, you're so good with math, why don't you share with the Board how you arrive at DEPO being such a better investment than HZNP! l'd love to see that calculation.
  • I could not find any breakout numbers for individual drugs for Q4 2016, so I went back to Q3 2016 to compare the difference between revenues for primary care vs Q1 2017. Assuming Q4 was better than Q3 at a minimum it seems the PBM’s really hosed us.
    Q3
    Pennsaid 80.2 million
    Duexis 47.6 million
    Vimovo 32.8 million
    Migergot 1.4 million
    Total revenue for PC Q3 was 161.8 million

    Q1 2017
    Pennsaid 41.6 million
    Duexis 17.7 million
    Vimovo 4.9 million
    Migergot 1.4 million
    Total revenue for PC Q3 was 65.6 million
    If we were able to sell 161.8 million in Q3 2016 and 65.6 million in Q1 2017 what advantage does selling through the PBM’s give us?
    96.2 million less in revenue plus HZNP had to pay them a commission for this abuse.
    This may be some experiment to prospective buyers for the PC business but so far it does not look like it is working. Plus I think we should keep Pennsaid the TAM for that drug is barely touched.
    GLTA
  • Hey Paul: you and that dumb sailor, Shelly, ought to fly to Ireland and sip scotch on the linoleum floor of HZNP HQ. LOL